BofA lowered the firm’s price target on 89bio (ETNB) to $29 from $30 and keeps a Buy rating on the shares. 89bio’s Q2 report was “highlighted by execution” with key readouts of FGF21 pegozafermin in MASH and SHTG still on track, says the analyst, who cites updated operating expense forecasts for the price target change.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB: